dermatology

News

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it

News

Incyte leads JAK push into eczema as FDA clears Opzelura cre...

The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US.

Partner Content

Partner Content

Taking a de-centralized approach to cure the Hepatitis C epi...

We compare approaches to combatting Hepatitis C

News

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including

News

Look out Dupixent, Lilly's lebrikizumab is on the march

Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner.

News

UCB's bimekizumab 'pre-approved' using NICE fast-track schem...

UCB's bimekizumab hasn't been approved for marketing in Europe yet, but has already been given the nod for NHS use in England and Wales under a new fast-track scheme introduced by NICE.

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Incyte leads JAK push into eczema as FDA clears Opzelura cre...

Taking a de-centralized approach to cure the Hepatitis C epi...

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

Look out Dupixent, Lilly's lebrikizumab is on the march

UCB's bimekizumab 'pre-approved' using NICE fast-track schem...

Precision Neuro breaks new ground in BCI technology

Discover a new era of healthcare panel engagement: Grounded ...

dermatology

Editor's Picks